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Background: Therapeutic hypothermia is a treatment modality that is increasingly used to improve clinical
neurological outcomes for ischemia-reperfusion injury-mediated diseases. Antibody-initiated classical complement
pathway activation has been shown to contribute to ischemia-reperfusion injury in multiple disease processes.
However, how therapeutic hypothermia affects complement activation is unknown. Our goal was to measure the
independent effect of temperature on complement activation, and more specifically, examine the relationship
between clinical hypothermia temperatures (31–33°C), and complement activation.
Methods: Antibody-sensitized erythrocytes were used to assay complement activation at temperatures ranging
from 0-41°C. Individual complement pathway components were assayed by ELISA, Western blot, and quantitative
dot blot. Peptide Inhibitor of complement C1 (PIC1) was used to specifically inhibit activation of C1.
Results: Antibody-initiated complement activation resulting in eukaryotic cell lysis was increased by 2-fold at 31°C
compared with 37°C. Antibody-initiated complement activation in human serum increased as temperature
decreased from 37°C until dramatically decreasing at 13°C. Quantitation of individual complement components
showed significantly increased activation of C4, C3, and C5 at clinical hypothermia temperatures. In contrast, C1s
activation by heat-aggregated IgG decreased at therapeutic hypothermia temperatures consistent with decreased
enzymatic activity at lower temperatures. However, C1q binding to antibody-coated erythrocytes increased at lower
temperatures, suggesting that increased classical complement pathway activation is mediated by increased C1
binding at therapeutic hypothermia temperatures. PIC1 inhibited hypothermia-enhanced complement-mediated
cell lysis at 31°C by up to 60% (P = 0.001) in a dose dependent manner.
Conclusions: In summary, therapeutic hypothermia temperatures increased antibody-initiated complement
activation and eukaryotic cell destruction suggesting that the benefits of therapeutic hypothermia may be mediated
via other mechanisms. Antibody-initiated complement activation has been shown to contribute to ischemia-reperfusion
injury in several animal models, suggesting that for diseases with this mechanism hypothermia-enhanced complement
activation may partially attenuate the benefits of therapeutic hypothermia.
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Therapeutic hypothermia improves neurological outcome
in ischemia-reperfusion injury (IRI) caused by cardiac
arrest [1], traumatic brain injury [2], stroke [3], acute liver
injury [4] and neonatal hypoxic ischemic encephalop-
athy [5]. In addition to decreased cerebral metabolism [6],
hypothermia appears to attenuate multiple processes that
contribute to tissue damage following IRI including neu-
roinflammation [7], excitotoxicty [8], mitochondrial dys-
function [9], apoptosis [10], free radical production [11],
seizure activity [12] and blood-brain barrier disruption
[13]. Hypothermia is also purported to stimulate protect-
ive cold shock proteins [14].
The complement system is an extremely potent inflam-
matory cascade composed of more than 30 plasma and
cell membrane proteins that plays major roles in innate
immune defense as well as many inflammatory diseases
including IRI. Clinical and experimental studies in mul-
tiple organ systems have shown that reperfusion following
ischemia results in local activation of the complement sys-
tem [15]. Complement activation in IRI is primarily medi-
ated by circulating natural antibodies (IgM) binding to
neo-antigens expressed on the surface of hypoxia-stressed
endothelial cells leading to classical complement pathway
activation or lectin pathway activation [16,17]. In addition
to direct complement-mediated endothelial cell damage
during reperfusion, complement induced neutrophil re-
cruitment and activation causes significant injury through
the phagocytic actions of macrophages, free radical pro-
duction and synthesis of toxic products [8]. Comple-
ment inhibition has been shown to be protective in animal
models of brain [18], kidney [19] and liver [20] IRI.
While several mechanisms of action for therapeutic
hypothermia have been proposed, the effect of hypothermia
on complement activation is unknown. Whether improved
outcomes in IRI could be due, in part, to hypothermia inhi-
biting or attenuating complement activation has not yet
been explored. Such a mechanism is plausible given that
complement activation is enzymatic and slows down dra-
matically at very low temperatures of 0 – 4°C [21,22]. How-
ever, whether the temperatures of clinical hypothermia,
31 - 33°C, would inhibit complement activation remains
untested. The increasing use of therapeutic hypothermia
in the treatment of IRI diseases makes understanding the
contribution of the complement system critical. These ex-
periments elucidate how therapeutic hypothermia temper-
atures modulate antibody-initiated complement activation.Methods
Ethics statement
Pooled normal human serum (NHS) was derived from the
blood of healthy human volunteers obtained with writ-
ten informed consent in accordance with an InstitutionalReview Board approved protocol (IRB 02-06-EX-0216,
Eastern Virginia Medical School).
Materials
Sheep erythrocytes were purchased from MP Biomedicals,
LLC. Anti-sheep-erythrocyte-IgM was purchased from
Rockland Incorporated. Sheep erythrocytes were incubated
with antibody at 30°C to generate antibody-sensitized cells
(EA), as previously described [23]. All antibody-sensitization
was performed at 30°C. Standard complement buffers were
prepared for hemolytic assays: GVBS++ (Veronal buffered
saline, 0.1% gelatin, 0.15 mM CaCl2, and 1.0 mM MgCl2),
Mg-EGTA-GVBS (Veronal buffered saline with 5 mM
MgCl2 and 8 mM EGTA), and GVBS
− − (Veronal buffered
saline, 0.1% gelatin, 0.01 M EDTA), Veronal Buffered Saline
(10 mM Barbital, 145 mM NaCl, pH 7.4). Peptide Inhibi-
tor of Complement C1 (PIC1) version AcPA, described
elsewhere [24], was synthesized by New England Peptide
(Gardner, MA). Lyophilized PIC1 was reconstituted in
DMSO. Pooled normal human serum (NHS) was prepared
as previously described [25]. C8-depleted human serum and
purified C1q were purchased from CompTech (Tyler, TX).
Hemolytic assays
Antibody-initiated complement hemolytic assays were
performed by incubating 100 μL EA with 0.2% NHS in
GVBS++. Hemolytic assays were performed for one hour
at temperatures ranging from 0°C to 37°C. A separate
assay was performed with more clinically relevant tem-
peratures of 31°, 33°, 35°, 37°, 39°, and 41°C. EA were also
incubated with water or buffer as controls. Hemolysis
reactions were quenched with 4 mL GVBS- - and the su-
pernatants recovered after sedimentation. Hemolysis
was quantified by spectrophotometry of the superna-
tants at 412 nm and normalized as previously described
[23]. Alternative complement pathway hemolytic assays
were performed by incubating rabbit erythrocytes (Comp-
Tech, Tyler, TX) with 4% NHS in Mg-EGTA-GVBS at
temperatures ranging from 0°C to 37°C. A separate assay
was performed with more clinically relevant temperatures
of 31°, 33°, 35°, 37°, 39°, and 41°C. Reactions were
quenched with 2 mL GVBS- -, sedimented and measured
as above.
C5a ELISA
Samples were generated by incubating 1% NHS with
400 μg/ml heat-aggregated IgG in GVBS++ at each
temperature for one hour. Heat-aggregated IgG was gen-
erated from purified human IgG (Gammagard, Baxter) as
described elsewhere [23]. The reaction was stopped with
EDTA-GVBS− − and the samples were measured by C5a
ELISA (R&D Systems). Background values from controls
of NHS and heat-aggregated human IgG incubated on ice
for one hour were subtracted.
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C3/C4 samples were generated by incubating C8-deficient
serum (to prevent hemolysis), 1% final, with 0.25 mL EA
in a total of 0.75 mL of GVBS++ for one hour at each
temperature. After incubation, the samples were washed
twice with water to remove hemoglobin, and the resulting
membrane bound C3/C4 was stripped using 25 mM me-
thylamine. These samples were quantitated by total C3
ELISA, iC3b ELISA, and C4 ELISA as previously de-
scribed [26]. C3 and C4 Western blot analysis was per-
formed as described elsewhere [26].
C1s western blot
A Western blot to assess C1s activation by heat aggre-
gated IgG has been previously described [27,28] One
microliter of partially purified C1 (0.2 mg/ml, Comple-
ment Technologies, Inc.), 5 μl of heat-aggregated IgG
(1:250 dilution from 50 μg/ml stock), and 5 μl of PBS
were combined on ice and samples incubated at the fol-
lowing temperatures: 31, 33, 35, 37, 39 and 41°C for 0,
30, 45, 60 and 90 minutes. After incubation, 4 μl of load-
ing buffer was added and each sample was boiled. Gel
electrophoresis on a 10% SDS-PAGE gel was performed
at 140 V for 60 minutes. The gel was then transferred to
a nitrocellulose membrane at 200 mA for 60 minutes.
The membrane was washed twice for five minutes in
PBS buffer and then blocked overnight in 5% NFDM-
PBS. The next day, the membrane was probed with pri-
mary antibody, Goat anti-C1s (Quidel), at a dilution of
1:2000 in 5% NFDM-PBS/0.1% Tween-20 for one hour
at room temperature. The membrane was washed 3X for
10 minutes with PBS/0.1% Tween-20. Then, the mem-
brane was probed with secondary antibody, Donkey
anti-goat IR680 (Li-cor Biosciences), at a dilution of
1:10,000 in 5% NFDM-PBS/0.1% Tween-20 for one hour
at room temperature. After washing the membrane 3X
with PBS/0.1% Tween-20, it was imaged on an Odyssey
imager to determine the amounts of the C1s heavy and
light chains characteristic of activated C1s relative to the
proenzyme species.
C1/C1q binding
C1 either from NHS (0.33% final) or C8-deficient serum
(CompTech), or purified C1q (Comp Tech) at 0.24 μg/
ml final, was combined with 100 μl of sensitized sheep
erythrocytes in a total volume of 0.75 ml of GVBS++ for
one hour at the various temperatures. These cells were
then washed twice with water and the resulting cell pel-
let was dissolved with 0.5% NP40. Membrane bound
C1q was analyzed by a quantitative Dot Blot assay. Pure
C1q was titrated onto PVDF membrane, along with the
samples, via a Dot Blot apparatus. The membrane was
blocked with 3% BSA, probed with a goat anti-C1q anti-
body (Comp Tech), and then an HRP-labeled rabbitanti-goat secondary antibody (Sigma-Aldrich). Bound anti-
body was detected by enhanced chemiluminescence. Using
the Quantity One software (Bio-Rad), grey scale values
were assigned to the pure C1q titration and the samples so
that a linear regression could be used to quantify the
amount of C1q in each sample.
PIC1 inhibition of cold-enhanced complement activation
Peptide Inhibitors of complement C1 (PIC1) specifically
inhibit C1 activation, as previously described [24,28].
Here we use the AcPA form (IALILEPICCQERAA) [24]
of PIC1. Preparations of 16.5% normal human serum
(NHS) in GVBS++ were incubated with 0.98 mM, 0.82 mM,
0.65 mM, 0.48 mM or 0.32 mM PIC1, DMSO vehicle con-
trol, or buffer control at 4°C for 1 hour. Samples were fur-
ther diluted 1:10 in GVBS++. Hemolysis reactions were
then performed with 100 μL of NHS sample plus 550 μL
of additional GVBS++ and 100 μL of EA over 1 hour at ei-
ther in 31° or 37°C. Controls and samples were processed
and measured by spectrophotometry at 412 nm.
Statistical analysis
Means and standard error of the means (SEM) were calcu-
lated from independent experiments. Statistical compari-
sons were made using one way ANOVA and Student’s
t-test where appropriate. Statistical analysis was performed
using GraphPad InStat 3 software.
Results
Functional hemolytic assays of complement activation at
hypothermic temperatures
In order to evaluate antibody-initiated complement-
activation at therapeutic hypothermia temperatures, we
tested antibody-sensitized sheep erythrocytes (EA) incu-
bated in normal human serum at 31°C-41°C and measured
hemolysis. In this CH50-type assay, hemolysis of antibody-
sensitized erythrocytes in human serum differed signifi-
cantly as a function of temperature (ANOVA P < 0.01).
There was 9-fold more hemolysis at 31°C compared with
41°C (t-test P < 0.01) and 2 fold more hemolysis at 31°C
compared with 37°C (t-test P = 0.01) (Figure 1A). These re-
sults show that antibody-initiated complement activation
increased at therapeutic hypothermia temperatures. Given
that complement activation is severely inhibited at near 0°C
temperatures, we then evaluated complement activation
for temperatures ranging from 0°C-37°C. Antibody-initiated
complement activation in human serum increased as tem-
perature decreased from 37°C to 24°C until dramatically de-
creasing at 13°C (Figure 1B). In these assays a similar 2-fold
increase in antibody-initiated complement activation
was noted comparing 31°C with 37°C (t-test P < 0.01).
From 0°C – 13°C complement activation was minimal.
We then tested whether similar effects would be ob-
served for the alternative complement pathway over
Figure 1 Functional hemolytic assays of complement activation. (A) CH50-type antibody-initiated complement assays incubating antibody-
sensitized erythrocytes (EA) with 0.2% human serum for 1 hour at 31-41°C showed that hemolysis of antibody-sensitized erythrocytes in human
serum differed significantly as a function of temperature (ANOVA P < 0.01). There is 2-fold more hemolysis at 31°C vs. 37°C (*t-test P = 0.01)
(P≤ 0.05 for the comparisons 31 vs. 37, 31 vs. 39, 31 vs. 41, 33 vs. 37, 33 vs. 39, 33 vs. 41, 35 vs. 39, 35 vs. 41, with significantly more hemolysis at
lower temperatures) Data are mean ± SEM for 4 independent experiments. (B) Evaluating antibody-initiated complement activation from 0-37°C
showed that hemolysis of antibody-sensitized erythrocytes in human serum differed significantly as a function of temperature (ANOVA P < 0.01).
There was 2.5-fold more hemolysis at 31°C vs. 37°C (*t-test P = 0.01). (P≤ 0.05 for the comparisons 31 vs. 37, 24 vs. 37, 19 vs. 37, with significantly
more hemolysis at lower temperatures). The trend of increased complement activation was reversed at 13°C. (No statistical difference between
hemolysis at 13 vs. 37 or 7 vs. 37). Data are mean ± SEM for 4 independent experiments. (C) AP50-type alternative complement pathway assays,
incubating rabbit erythrocytes with 4% human serum in Mg-EGTA-GVBS for 30 minutes at 31-41°C showed that temperature did not influence
complement-mediated cell lysis over therapeutic hypothermia temperatures (ANOVA P = 0.45). Data are mean ± SEM for 4 independent
experiments. (D) Evaluating alternative pathway activation from 0-37°C showed that alternative pathway activation was significantly inhibited at
24°C and below. There was no difference in the degree of hemolysis at 31°C vs. 37°C) Data are mean ± SEM for 4 independent experiments.
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alternative complement pathway assay, temperature did
not alter complement-mediated cell lysis at therapeutic
hypothermia temperatures (ANOVA P = 0.45) (Figure 1C).
Testing alternative pathway activation from 0°C – 37°C
demonstrated that activation was significantly inhibited at
24°C and below (Figure 1D). These results show that
antibody-initiated complement activation increased at clin-
ical hypothermia temperatures compared with euthermia,
suggesting that antibody-initiated complement activation
occurring during reperfusion at hypothermic temperaturescould potentially increase complement-mediated tissue
damage.
Complement cascade activation assays
Complement-mediated hemolysis results from pores
generated by the membrane attack complex (MAC),
suggesting that increased terminal complement cascade
activation was occurring at lower temperatures. In order
to further evaluate activation of the terminal comple-
ment cascade we measured C5a generation in response
to a different antibody-initiated complement activator,
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phylatoxin important for phagocytic cell recruitment and
activation [29] and implicated in contributing to tissue
damage in many inflammatory diseases processes [30].
Heat-aggregated IgG incubated with normal human serum
demonstrated that C5a generation differed significantly asFigure 2 Complement cascade activation assays. (A) Heat-aggregated
C5a generation differed significantly as a function of temperature (ANOVA
37°C (*t-test P =0.05). Data are mean ± SEM for 4 independent experiments
C8-deficient serum (to prevent hemolysis) with 0.25 mL EA for one hour at
as a function of temperature (ANOVA P = 0.5). (C) Cell membrane bound iC
with a 2-fold increase at 31°C vs. 37°C (t-test P = 0.04). Data are mean ± SEM
analysis of membrane-bound C3-fragments confirmed that iC3b was the p
a function of temperature (ANOVA P = 0.04). There was an almost 2-fold in
mean ± SEM for 4 independent experiments. (F) A representative Westerna function of temperature (ANOVA P < 0.01). There was
a >2-fold increase in C5a generation at 31°C compared
with 37°C (t-test P =0.05) (Figure 2A). These data show
that at clinical hypothermia temperatures terminal com-
plement cascade activation increased, consistent with
the CH50-type assay, and suggests that increased C5aIgG 1% normal human serum for 1 hour at 31-41°C demonstrated that
P < 0.01). There was a 2.5 fold increase in C5a generation at 31°C vs.
. C3/C4-analysis samples were generated by incubating 1%
31-41°C. (B) Total C3-fragment opsonization did not differ significantly
3b differed significantly as a function of temperature (ANOVA P < 0.01),
for 4 independent experiments. (D) A representative Western blot
redominant form. (E) C4-fragment opsonization differed significantly as
crease in C4 generation at 31°C vs. 37°C (*t-test P = 0.05). Data are
blot analysis demonstrated a mixture of C4b, iC4b and C4d fragments.
Figure 3 C1s activation by heat-aggregated IgG for increasing
temperatures. One μg of partially purified human C1 was
incubated with heat-aggregated IgG at 31-41 C for 0–90 minutes.
C1s activation, as measured by generation of C1s heavy and light
chains by Western blot methodology, was quantified by Odyssey
imaging and demonstrated decreased activation of C1s at therapeutic
hypothermia temperatures (ANOVA P < 0.01), with a 5-fold decrease at
31°C vs. 37°C (*t-test P < 0.01). Data are mean ± SEM for 3 independent
experiments.
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phil recruitment and activation enhancing inflammation
and host tissue damage during reperfusion.
C3 is the central component of the complement cas-
cades and its activation results in generation of the ana-
phylatoxin C3a and opsonization of targets with the
C3-fragments, C3b and iC3b. We tested C3 activation and
opsonization with C3b/iC3b by incubating EA with C8-
deficient serum (to prevent hemolysis). Though total C3-
fragment opsonization as a function of temperature was
not statistically significant (ANOVA P = 0.5) (Figure 2B),
cell membrane bound iC3b differed significantly as a func-
tion of temperature (ANOVA P < 0.01), with a 2-fold in-
crease at 31°C versus 37°C (t-test P = 0.04) (Figure 2C).
Western blot analysis of membrane-bound C3-fragments
confirmed that iC3b was the predominant form and sug-
gested increased iC3b deposition at lower temperatures
(Figure 2D) consistent with ELISA data. These data show
that C3 activation and iC3b opsonization increased at
clinical hypothermia temperatures, suggesting that these
temperatures could increase opsonization of host cells
(e.g. endothelial cells) during reperfusion targeting them
for phagocyte attack.
In order to specifically evaluate the classical complement
pathway, we tested C4 activation by incubating EA with
C8-deficient serum. C4-fragment binding differed signi-
ficantly as a function of temperature (ANOVA P = 0.04).
There was an almost 2-fold increase in C4 generation at
31°C compared with 37°C (t-test P = 0.05) (Figure 2E).
Western blot analysis demonstrated a mixture of C4b,
iC4b and C4d fragments (Figure 2F) and suggested in-
creased C4-fragment binding at 31°C. These findings show
that classical pathway activation is increased at therapeutic
hypothermia temperatures and suggests that C1 activation,
which cleaves C4, is also increased at these temperatures.C1 activation and binding
C1 is a complex molecule consisting of a pattern (e.g.,
IgG/M) recognition component C1q, which associates
with the serine protease tetramer C1r-C1s-C1s-C1r. When
the C1q portion of the molecule binds to IgG/M, it causes
auto-activation of the enzymatic tetramer leading to acti-
vation of C4 and the classical pathway cascade. Therefore,
increased activation of C1 at lower temperatures could be
caused by increased C1q binding, or increased enzymatic
activity, or both. C1 enzymatic activation was tested at in-
creasing temperatures over a 90 minute period using heat-
aggregated IgG incubated with partially purified C1. C1s
activation was assayed by the conversion of precursor C1s
to its activated heavy and light chain forms, as previously
described [27,28]. C1s activation decreased at therapeutic
hypothermia temperatures, suggesting decreased enzym-
atic activity at lower temperatures (Figure 3).C1q and C1 binding was tested by incubating EA with
purified C1q, or normal human serum, or C8-deficient
serum. In each case, C1/C1q binding to EA showed a con-
sistent trend of increasing at lower temperatures (Figures 4A,
B, and C), suggesting that increased classical complement
pathway activation is likely mediated by increased C1 bind-
ing at therapeutic hypothermia temperatures. These findings
may also explain the lack of hypothermia-enhanced alterna-
tive pathway activation where initiation is not mediated by a
pattern recognition molecule (e.g. C1q) binding event.
Inhibition of C1-mediated complement activation
In order to further elucidate the role of C1 in antibody-
initiated hypothermia-enhanced complement activation, we
tested a specific inhibitor of C1 activation, PIC1, (Peptide In-
hibitor of complement C1) [23,24,27,28]. In the CH50-type
assay, PIC1 successfully inhibited hypothermia-enhanced
complement activation at 31°C in a dose-dependent man-
ner by up to 60% compared with untreated control
(ANOVA P = < 0.01) (Figure 5). At 0.98 mM PIC1 inhib-
ited hypothermia-enhanced (31°C) complement-mediated
cell lysis to a level not statistically different from that for
euthermia (37°C) (t-test P = 0.44). These results suggest
that hypothermia-enhanced antibody-initiated complement
activation can be blocked using a specific inhibitor of C1
activation.
Discussion
The clinical benefit of therapeutic hypothermia in moder-
ating IRI and improving neurological outcomes is modest,
but clear [31,32]. Therapeutic hypothermia offers an 11%
reduction in risk of death or disability in neonatal hypoxic
Figure 4 C1/C1q binding at therapeutic hypothermia temperatures. C1q binding was tested by incubating antibody-sensitized erythrocytes
with (A) purified C1q, (B) normal human serum, or (C) C8-deficient serum for one hour at 31-41°C. In each case, there was a consistent trend of
increased C1q binding to EA at lower temperatures. Data are mean ± SEM for 4 independent experiments.
Figure 5 Peptide inhibitor of C1 (PIC1) and hypothermia-
enhanced complement-mediated hemolysis. Human serum
(16.5%) was pre-incubated with 0.98 mM, 0.82 mM, 0.65 mM,
0.48 mM or 0.32 mM PIC1, DMSO vehicle control, or buffer control
before performing the CH50-type assay at 31° or 37°C. PIC1 inhibited
hypothermia-enhanced complement activation and hemolysis at
31°C for all doses tested up to 60% inhibition for 0.98 mM PIC1
compared with 31°C untreated (*ANOVA P <0.01). Increasing
concentrations of PIC1 showed a significant dose dependent inhibition of
hypothermia-enhanced complement activation at 31°C for all doses tested.
At 31°C, 0.98 mM of PIC1 inhibited complement mediated cell lysis to a
level equivalent with euthermia (37°C) (t-test P = 0.44) Data are
mean ± SEM for 3 independent experiments.
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Therapeutic hypothermia appears to have beneficial effects
for several mechanisms that likely contribute to the patho-
genesis of IRI, but all of the effects of cooling the human
body are unknown. It is reasonable to expect that a non-
targeted treatment such as therapeutic hypothermia may
have some unrecognized detrimental actions, which could
partially attenuate the positive effects. The most striking
finding from our studies is that therapeutic hypothermia
temperatures increase antibody-initiated complement acti-
vation enhancing inflammation, opsonization, and destruc-
tion of eukaryotic cells in vitro. Thus, our data strongly
suggests that the therapeutic effect of hypothermia may
not be mediated by reducing complement activation, but
rather, clinical benefit is derived via other mechanisms.
These data suggest that therapeutic hypothermia tempera-
tures likely increase antibody-initiated complement activa-
tion in vivo (Figure 6), potentially partially attenuating the
clinical benefits of therapeutic hypothermia in the treat-
ment of IRI.
Our data show that increased complement activation
at lower temperatures was mediated by antibody-initiated
complement activation, but the alternative pathway was un-
affected by the temperatures tested. Therapeutic hypo-
thermia temperatures increased complement-mediated cell
lysis demonstrating enhanced membrane attack complex
Figure 6 Model of antibody-initiated complement activation in ischemia reperfusion injury and hypothermia effects on complement
activation. Hypoxic insult induces expression of 'neoantigens' on the surface of vascular endothelial cells. These neoantigens are recognized by
natural antibodies (IgM) initiating complement activation leading to downstream inflammatory effectors. Therapeutic hypothermia temperatures
were shown to increase C1/C1q binding, increase opsonization with C4-fragments and C3-fragments, increase C5a anaphylatoxin generation, and
increase eukaryotic cell lysis via membrane attack complex (MAC) formation. Increases in complement function demonstrated in this study are
shown in grey. PIC1 inhibits complement activation at C1 preventing C4 activation.
Shah et al. Journal of Translational Medicine 2014, 12:181 Page 8 of 10
http://www.translational-medicine.com/content/12/1/181pore formation. At lower temperatures there was increased
C5a generation, which recruits and activates neutrophils
enhancing local inflammation. Increased iC3b opsonization
of eukaryotic cells occurred at lower temperatures, which
targets them for attack by phagocytic cells. Increased C4 ac-
tivation at low temperatures suggested increased activation
at C1, which cleaves C4. Testing activation of the enzymatic
components of C1 showed decreased enzymatic activity
at lower temperatures, which is a common property of en-
zymatic reactions. However, multiple assays testing C1 or
C1q binding showed a consistent trend toward increased
binding to antibody-sensitized cells at lower temperatures.
Increased binding of molecules often occurs at lower tem-
peratures [34] and suggested that increased binding of C1
may be responsible for increased antibody-initiated comple-
ment activation despite decreased enzymatic activity. In-
creased antibody-initiated complement activation was not
mediated by temperature effects on antibody-binding, be-
cause all antibody-sensitization procedures were performed
at 30°C. Using serum from a patient with cutaneous vascu-
litis, it was found that cryoglobulin increased activation of
the complement system at 20°C [35].
It is notable that antibody-initiated complement activa-
tion was decreased at 41°C compared with 37°C. We
speculate that decreased antibody-initiated complement
activation at febrile temperatures may be a mechanism of
dampening classical pathway activation after systemic in-
flammation with cytokines and TNF has been achieved.
Classical pathway activation occurs extremely early in in-
flammation and once initiated, complement activation will
be perpetuated by the positive-feedback loop of the alter-
native pathway, which does not appear to be affected by
febrile temperatures. Thus, this may be a down-regulatory
mechanism to decrease further activation of the classical
pathway and moderating potential complement-mediateddamage to the host. Although mechanistically different,
fever decreasing classical pathway activation may be func-
tionally similar to soluble TNF-receptor generation down-
regulating TNF effects late in inflammation [36,37].
In order to elucidate the mechanism of hypothermia-
enhanced antibody-initiated complement activation, we
tested a specific inhibitor of C1 activation (Figure 6).
PIC1 successfully inhibited hypothermia-enhanced com-
plement activation at 31°C to a level similar to that
which occurred at euthermia (37°C), consistent with C1-
mediated activation.
Our findings differ from a study demonstrating attenu-
ated complement activation following hypothermia in vivo
in a cohort of cardiopulmonary bypass patients [38]. How-
ever, the findings in the study cannot be attributed to
hypothermia alone, since the practices of hemodilution
and heparinization in cardiopulmonary bypass utilized in
this study likely confound the association as they are inde-
pendent causes of complement inhibition [39]. One of the
limitations of this study is that it does not model IRI.
However, this limitation allowed us to explore the inde-
pendent effect of hypothermia on antibody-initiated com-
plement activation. Future directions include testing the
effects of hypothermia in the Vannucci model of rat brain
IRI [40] and elucidating the contribution of the lectin and
classical pathway in hypothermia enhanced complement
activation.
Conclusions
Therapeutic hypothermia temperatures increased antibody-
initiated complement activation and eukaryotic cell destruc-
tion suggesting that the benefits of therapeutic hypothermia
may be mediated via other mechanisms. A peptide inhibitor
of complement (PIC1) significantly inhibited this enhanced
complement activation. Antibody-initiated complement
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reperfusion injury in several animal models, suggesting that
for diseases with this mechanism hypothermia-enhanced
complement activation may partially attenuate the benefits
of therapeutic hypothermia. Future directions include test-
ing the relationship between complement activation and
hypothermia in an animal model of neonatal hypoxic-
ischemic encephalopathy.
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